Christina Villard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christina Villard has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Carl Jorns
Department of Transplantation Surgery, Karolinska University Hospital, Stockholm, Sweden
4 shared publications- Rebecka Hultgren
Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm
4 shared publications - Ernesto Sparrelid
Department of Clinical Science, Intervention and Technology, Division of Surgery and Oncology, Karolinska Institutet, Stockholm, Sweden
3 shared publications - Per Eriksson
Cardiology Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
3 shared publications Annika Bergquist
Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden
2 shared publications- Carl Jorns
Division of Transplantation Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 23 July 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 30 (11) , 1132-1144
Normothermic regional perfusion in controlled DCD liver procurement: Outcomes of the Swedish national implementation protocol
Liver transplantation using donors after controlled circulatory death (cDCD) is associated with poorer graft survival and increased incidence of non-anastomotic biliary strictures (NAS) compared to livers procured from brain dead donors (DBD). The use of Normothermic regional perfusion (NRP) during cDCD procurement may improve post-transplant outcome and reduce the incidence of NAS. In Sweden cDCD liver transplantation was introduced through a national pilot protocol with mandatory NRP. This study aims to evaluate the outcome of cDCD liver transplantation during the pilot period. Donor and recipient data were collected on all cDCD liver transplants during the pilot period between 2020 – December 2022. Outcome on NAS, patient- and graft survival, early allograft dysfunction, acute kidney injury, and comprehensive complication index was compared to a matched cohort of 28 patients transplanted with a DBD liver between 2018-2022. 18 patients were transplanted with a liver from a cDCD donor after using NRP. Mean functional warm ischemia time was 29±6 minutes. Mean lactate reduction during NRP was 8.7±2.4 mmol/L, end NRP perfusate ALT was 1.4±1 µkat/L. When comparing cDCD liver transplant recipients to DBD, no significant differences were observed in the incidence of NAS, patient and graft survival, comprehensive complication index, early allograft dysfunction, nor acute kidney injury. Study protocol MRCP in cDCD patients showed no signs of subclinical biliary strictures. Evaluation of the Swedish national pilot of cDCD liver transplantation with mandatory NRP shows comparable outcomes to a matched DBD cohort with 94.4 one-year patient and graft survival and no incidence of NAS within the first year. Export
- 23 July 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 30 (11) , 1132-1144
Open AccessNormothermic regional perfusion in controlled DCD liver procurement: Outcomes of the Swedish national implementation protocol
Liver transplantation using donors after controlled circulatory death (cDCD) is associated with poorer graft survival and increased incidence of non-anastomotic biliary strictures (NAS) compared to livers procured from brain dead donors (DBD). The use of Normothermic regional perfusion (NRP) during cDCD procurement may improve post-transplant outcome and reduce the incidence of NAS. In Sweden cDCD liver transplantation was introduced through a national pilot protocol with mandatory NRP. This study aims to evaluate the outcome of cDCD liver transplantation during the pilot period. Donor and recipient data were collected on all cDCD liver transplants during the pilot period between 2020 – December 2022. Outcome on NAS, patient- and graft survival, early allograft dysfunction, acute kidney injury, and comprehensive complication index was compared to a matched cohort of 28 patients transplanted with a DBD liver between 2018-2022. 18 patients were transplanted with a liver from a cDCD donor after using NRP. Mean functional warm ischemia time was 29±6 minutes. Mean lactate reduction during NRP was 8.7±2.4 mmol/L, end NRP perfusate ALT was 1.4±1 µkat/L. When comparing cDCD liver transplant recipients to DBD, no significant differences were observed in the incidence of NAS, patient and graft survival, comprehensive complication index, early allograft dysfunction, nor acute kidney injury. Study protocol MRCP in cDCD patients showed no signs of subclinical biliary strictures. Evaluation of the Swedish national pilot of cDCD liver transplantation with mandatory NRP shows comparable outcomes to a matched DBD cohort with 94.4 one-year patient and graft survival and no incidence of NAS within the first year. Export
- Open Access
- 29 March 2024
- Published by BMJ in eGastroenterology
- Vol. 2 (1) , e100045
Treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis: a comprehensive review
Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease, characterised by persistent biliary inflammation resulting in fibrosis and multifocal strictures of the biliary tree. The course of disease is highly variable, ranging from asymptomatic disease to the development of end-stage biliary cirrhosis and an increased risk of biliary tract cancer (BTC), particularly cholangiocarcinoma (CCA). PSC is the most important risk factor for CCA in younger people, with a reported lifetime prevalence ranging from 6% to 13%. Perihilar CCA (pCCA), involving the hepatic duct bifurcation, is the most common CCA amounting to approximately 50% of all cases, whereas intrahepatic CCA (iCCA), located within the hepatic parenchyma, represents less than 10%. CCA is an aggressive tumour, and only a minority of patients are amenable to surgical resection with curative intent. Radical liver resection and liver transplantation are potentially curative therapeutic options in patients with PSC in the absence of metastatic or locally advanced disease. Liver transplantation with neoadjuvant chemoradiation could be considered in selected patients with unresectable pCCA and without pretreatment in patients with PSC with bile duct high-grade dysplasia. Recent reports demonstrating favourable outcomes in transplanted patients with small iCCA and patients with locally advanced disease following neoadjuvant therapy have challenged the previously described poor outcome in transplanted patients with iCCA. Treatment for CCA is challenged by the inherent difficulties in enabling an early diagnosis and thereby preventing an otherwise dismal prognosis. This comprehensive review aims to describe therapeutic considerations and challenges in patients with PSC-CCA.
- 29 March 2024
- Published by BMJ in eGastroenterology
- Vol. 2 (1) , e100045
Open AccessTreatment of cholangiocarcinoma in patients with primary sclerosing cholangitis: a comprehensive review
Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease, characterised by persistent biliary inflammation resulting in fibrosis and multifocal strictures of the biliary tree. The course of disease is highly variable, ranging from asymptomatic disease to the development of end-stage biliary cirrhosis and an increased risk of biliary tract cancer (BTC), particularly cholangiocarcinoma (CCA). PSC is the most important risk factor for CCA in younger people, with a reported lifetime prevalence ranging from 6% to 13%. Perihilar CCA (pCCA), involving the hepatic duct bifurcation, is the most common CCA amounting to approximately 50% of all cases, whereas intrahepatic CCA (iCCA), located within the hepatic parenchyma, represents less than 10%. CCA is an aggressive tumour, and only a minority of patients are amenable to surgical resection with curative intent. Radical liver resection and liver transplantation are potentially curative therapeutic options in patients with PSC in the absence of metastatic or locally advanced disease. Liver transplantation with neoadjuvant chemoradiation could be considered in selected patients with unresectable pCCA and without pretreatment in patients with PSC with bile duct high-grade dysplasia. Recent reports demonstrating favourable outcomes in transplanted patients with small iCCA and patients with locally advanced disease following neoadjuvant therapy have challenged the previously described poor outcome in transplanted patients with iCCA. Treatment for CCA is challenged by the inherent difficulties in enabling an early diagnosis and thereby preventing an otherwise dismal prognosis. This comprehensive review aims to describe therapeutic considerations and challenges in patients with PSC-CCA.
- Open Access
- 22 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (1) , 79
The Role of Immunoglobulin G4 in Outcomes of Primary Sclerosing Cholangitis
Introduction: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease that is characterized by an inflammatory and fibrotic process affecting bile ducts which eventually develops into liver cirrhosis and liver failure. The aim of this study was to investigate serum IgG subclass distribution in patients with PSC and its possible association with PSC outcomes. Patients and methods: We performed a retrospective analysis of 181 patients who had been diagnosed with PSC between January 1970 and December 2015 and followed at our outpatient clinic. Their demographic, immunological, and clinical characteristics were recorded and analyzed. Results: This study included 181 patients with PSC (120 males, 61 females). There was no association between IgGs and the development of autoimmune hepatitis, cirrhosis, cholangiocarcinoma, liver transplantation, inflammatory bowel disease, and colectomy. Patients with elevated IgG4 had statistically significant higher rates of cholangitis (p = 0.02) and endoscopic retrograde cholangiopancreatography (ERCP) (p = 0.009). High IgG4 values were observed in nine patients who underwent ERCP. In these nine patients, on average, IgG4 was evaluated 5 years after ERCP (min 3 days, max 11 years). Subanalysis considering only IgG4 values evaluated before ERCP showed no significant difference but remains significant if we consider IgG4 values after ERCP. Conclusion: Elevated IgG4 in our study showed a possible association with higher rates of cholangitis and ERCP among patients with primary sclerosing cholangitis. It seems that IgGs may be a useful tool for the prediction of outcomes in patients with PSC. A prospective study is necessary, especially to study the trends of IgGs values during disease as well as the role of possible seroconversion.
- 22 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (1) , 79
Open AccessThe Role of Immunoglobulin G4 in Outcomes of Primary Sclerosing Cholangitis
Introduction: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease that is characterized by an inflammatory and fibrotic process affecting bile ducts which eventually develops into liver cirrhosis and liver failure. The aim of this study was to investigate serum IgG subclass distribution in patients with PSC and its possible association with PSC outcomes. Patients and methods: We performed a retrospective analysis of 181 patients who had been diagnosed with PSC between January 1970 and December 2015 and followed at our outpatient clinic. Their demographic, immunological, and clinical characteristics were recorded and analyzed. Results: This study included 181 patients with PSC (120 males, 61 females). There was no association between IgGs and the development of autoimmune hepatitis, cirrhosis, cholangiocarcinoma, liver transplantation, inflammatory bowel disease, and colectomy. Patients with elevated IgG4 had statistically significant higher rates of cholangitis (p = 0.02) and endoscopic retrograde cholangiopancreatography (ERCP) (p = 0.009). High IgG4 values were observed in nine patients who underwent ERCP. In these nine patients, on average, IgG4 was evaluated 5 years after ERCP (min 3 days, max 11 years). Subanalysis considering only IgG4 values evaluated before ERCP showed no significant difference but remains significant if we consider IgG4 values after ERCP. Conclusion: Elevated IgG4 in our study showed a possible association with higher rates of cholangitis and ERCP among patients with primary sclerosing cholangitis. It seems that IgGs may be a useful tool for the prediction of outcomes in patients with PSC. A prospective study is necessary, especially to study the trends of IgGs values during disease as well as the role of possible seroconversion.
- Open Access
- 15 January 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (4) , 688-699
Prognostic influence of multiple hepatic lesions in resectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis
- 15 January 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (4) , 688-699
Open AccessPrognostic influence of multiple hepatic lesions in resectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis
- Open Access
- 18 November 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 78 (3) , 604-613
Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis
- 18 November 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 78 (3) , 604-613
Open AccessProspective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis
- Open Access
- 21 June 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (12) , 2432-2439
Prediction of survival in patients with colorectal liver metastases- development and validation of a prognostic score model
- 21 June 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (12) , 2432-2439
Open AccessPrediction of survival in patients with colorectal liver metastases- development and validation of a prognostic score model
- Open Access
- 11 March 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (7) , 1656-1663
Prognostic impact of inter-metastatic heterogeneity of viable tumour cells in colorectal liver metastases
- 11 March 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (7) , 1656-1663
Open AccessPrognostic impact of inter-metastatic heterogeneity of viable tumour cells in colorectal liver metastases
- 1 December 2021
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 74 (6) , 2121
Reply
- Open Access
- 1 December 2021
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 74 (6) , 2023-2029
Sex hormones in men with abdominal aortic aneurysm
- 1 December 2021
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 74 (6) , 2023-2029
Open AccessSex hormones in men with abdominal aortic aneurysm
- Open Access
- 1 August 2021
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 10 (4) , 476-485
The potential use of extended criteria donors and eligible recipients in liver transplantation for unresectable colorectal liver metastases in Central Sweden
The potential use of extended criteria donors and eligible recipients in liver transplantation for unresectable colorectal liver metastases in Central Sweden Christina Villard, Joakim Westman, Jonas Frank, Oystein Jynge, Ernesto Sparrelid, Carl Jorns
- 1 August 2021
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 10 (4) , 476-485
Open AccessThe potential use of extended criteria donors and eligible recipients in liver transplantation for unresectable colorectal liver metastases in Central Sweden
The potential use of extended criteria donors and eligible recipients in liver transplantation for unresectable colorectal liver metastases in Central Sweden Christina Villard, Joakim Westman, Jonas Frank, Oystein Jynge, Ernesto Sparrelid, Carl Jorns